Teladoc Health Inc (NYSE:TDOC) Given Consensus Rating of “Hold” by Brokerages

Shares of Teladoc Health Inc (NYSE:TDOC) have been assigned a consensus rating of “Hold” from the twenty-six analysts that are presently covering the firm, Marketbeat.com reports. Fifteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $159.91.

TDOC has been the topic of several research reports. CSFB increased their price target on shares of Teladoc Health from $152.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, April 30th. KeyCorp raised their price objective on shares of Teladoc Health from $180.00 to $195.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Canaccord Genuity raised their price objective on shares of Teladoc Health from $130.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Credit Suisse Group raised their price objective on shares of Teladoc Health from $152.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th. Finally, Zacks Investment Research cut shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $171.00 price objective on the stock. in a research note on Thursday, May 28th.

NYSE:TDOC traded up $10.04 during midday trading on Friday, hitting $208.89. The company’s stock had a trading volume of 2,414,600 shares, compared to its average volume of 3,085,267. Teladoc Health has a fifty-two week low of $54.58 and a fifty-two week high of $210.86. The firm’s 50 day moving average is $180.73 and its 200-day moving average is $140.26. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.14 and a quick ratio of 6.14.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.05). Teladoc Health had a negative return on equity of 10.60% and a negative net margin of 16.24%. The business had revenue of $180.80 million during the quarter, compared to analyst estimates of $180.64 million. During the same quarter last year, the company posted ($0.43) EPS. Teladoc Health’s quarterly revenue was up 40.6% compared to the same quarter last year. On average, sell-side analysts forecast that Teladoc Health will post -1.12 EPS for the current year.

In other Teladoc Health news, Director William H. Frist sold 370 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $180.00, for a total value of $66,600.00. Following the transaction, the director now owns 5,788 shares in the company, valued at approximately $1,041,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Goldstein sold 8,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $163.00, for a total value of $1,304,000.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $1,304,000. The disclosure for this sale can be found here. Insiders have sold a total of 290,628 shares of company stock worth $50,037,840 in the last quarter. Insiders own 3.42% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of TDOC. Total Clarity Wealth Management Inc. acquired a new stake in shares of Teladoc Health in the 4th quarter worth $25,000. Tower Research Capital LLC TRC acquired a new stake in shares of Teladoc Health in the 4th quarter worth $28,000. PrairieView Partners LLC acquired a new stake in shares of Teladoc Health in the 1st quarter worth $31,000. Pathstone Family Office LLC acquired a new stake in shares of Teladoc Health in the 1st quarter worth $31,000. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Teladoc Health in the 1st quarter worth $35,000. 97.66% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: volatile stocks

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.